Beckman Coulter Life Sciences signed a definitive agreement to acquire m2p-labs, a privately held, microbioreactor manufacturer based in Baesweiler, Germany. m2p-labs is best known for its transformative BioLector plate-based microbioreactors, which support automated solutions for screening and bioprocess development.
“Innovation defines our future,” said Greg Milosevich, President, Beckman Coulter Life Sciences. “m2p-labs core product line complements our existing cell health, liquid handling and laboratory automation business. Our collective team has the opportunity to enhance time-saving solutions for cell line development and process development workflows.”
“m2p-labs and Beckman Coulter Life Sciences share a common vision of accelerating answers, enabling the faster discovery and development of life-changing advances in medicine,” said, Matthias Eggers, Managing Director, m2p-labs. “We are excited to join, and expand, a powerful team to provide invaluable resources to biologics customers around the world.”
m2p-labs was supported in several financings rounds by FIDURA Private Equity Funds and High-Tech Gründerfonds. “It was a privilege for us to work with management on growing m2p-labs to a leading microbioreactor vendor with global reach,” said Klaus Ragotzky, Managing Director and Chairman of the Advisory Board, FIDURA.
m2p-labs associates and products will transition into Beckman Coulter Life Sciences’ Biotechnology Business Unit. The company’s existing Baesweiler, Germany site will remain operational.